KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Operating Expenses (2017 - 2025)

Rigel Pharmaceuticals has reported Other Operating Expenses over the past 12 years, most recently at $6.0 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 2.87% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $19.6 million, up 5.22%, while the annual FY2025 figure was $19.6 million, 5.22% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $6.0 million at Rigel Pharmaceuticals, up from $4.8 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $14.5 million in Q4 2022 and troughed at $121000.0 in Q1 2022.
  • A 5-year average of $3.3 million and a median of $2.4 million in 2024 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: skyrocketed 1148.6% in 2021 and later tumbled 73.91% in 2023.
  • Year by year, Other Operating Expenses stood at $4.0 million in 2021, then soared by 262.45% to $14.5 million in 2022, then crashed by 73.91% to $3.8 million in 2023, then surged by 52.74% to $5.8 million in 2024, then grew by 2.87% to $6.0 million in 2025.
  • Business Quant data shows Other Operating Expenses for RIGL at $6.0 million in Q4 2025, $4.8 million in Q3 2025, and $4.5 million in Q2 2025.